Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report (B4Z-MC-B026)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/28855
• EU PAS number:
  EUPAS17371
• Study ID:
  28855
• Official title and acronym:
  Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report (B4Z-MC-B026)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Netherlands

  Sweden

  United Kingdom
• Study description:
  The objective of this study is to describe atomoxetine (Strattera) utilization patterns for patients treated in the United Kingdom (UK), Germany, the Netherlands, and Sweden from the time period of 2012 through 2016.
• Study status:
  Finalised

Research institutions and networks

Institutions

Real World Evidence Solutions, IMS Health

France

Study timelines

Date when funding contract was signed

Planned: 26/08/2013

Actual: 26/08/2013

Study start date

Planned: 01/04/2017

Actual: 01/04/2017

Date of final study report

Planned: 30/03/2018

Actual: 12/03/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Study protocol

Initial protocol

B026 PASS

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)